WithdrawnNot Applicable

Hepatitis C in Prison: Study of Screening and Rapid Treatment (HEPAPRIS)

Stopped: No patient eligible

France0Started 2023-01

Plain-language summary

Due to the high prevalence of HCV in prison and the risk of transmission between inmates, the management of hepatitis C and its treatment must be optimal following the recommendations of AFEF. The purpose of this study is to assess the treatment starting delay from the date of incarceration of inmates with chronic HCV infection (hepatitis C).

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patient (\>/= 18 years old), * Persons detained at the Paris-La Santé Penitentiary Center (CPPLS) coming from the state of freedom or transferred from another penitentiary establishment * Serology HCV positive Exclusion Criteria: * Major psychiatric disorders with loss of discernment * Persons under guardianship or curatorship * Persons not affiliated to a social security scheme

What they're measuring

Delay to treat inmates with chronic HCV infection.

Timeframe: up to 8 days from incarceration

Trial details

NCT IDNCT05649202

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01

View on ClinicalTrials.gov More Chronic HIV Infection trials